- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
One Size Dose Doesn't Fit All
San Francisco - Results from premarketing clinical trials indicate that the usual efalizumab (Raptiva) dosage for the treatment of psoriasis will involve ongoing therapy with 1 mg/kg in the vast majority of patients, but alternate dosing regimens for fine-tuning management may benefit certain subgroups of patients, Kim A. Papp, M.D., said at the annual meeting of the American Academy of Dermatology.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Safety Considerations in Pediatric Atopic Dermatitis Treatments
Melinda Gooderham, MD, MSc, FRCPC: Reaffirming Delgocitinib Safety With Minimal Absorption, Maximum Confidence
Quality of Life Impact: Supporting Patients With GPP
Related Content
